首页> 外文期刊>Thoracic cancer. >Predictors of survival in patients who underwent video‐assisted thoracic surgery talc pleurodesis for malignant pleural effusion
【24h】

Predictors of survival in patients who underwent video‐assisted thoracic surgery talc pleurodesis for malignant pleural effusion

机译:接受电视胸腔镜治疗滑石粉对恶性胸腔积液患者的生存率预测

获取原文
获取外文期刊封面目录资料

摘要

Background Patients with malignant pleural effusion have a limited life expectancy. An increase in pleural and oncological treatment options and more accurate prognostic evaluation may help individualize treatment strategies. The aim of this study was to identify the prognostic indicators of overall survival (OS) after video-assisted thoracic surgery (VATS) talc pleurodesis for malignant pleural effusion. Methods We examined the medical records of all consecutive patients with malignant pleural effusion who underwent VATS talc pleurodesis from 2006 to 2008 at the Samsung Medical Center. Univariate and multivariate analyses were used to identify predictors of OS after VATS talc pleurodesis. Results During the study period, 91 patients underwent VATS talc pleurodesis to treat malignant pleural effusion. Early (within 30 days) and late (within 90 days) postoperative mortality rates were 9.9% (9 patients), and 25.3% (23), respectively. Median survival time after VATS talc pleurodesis was 10.5 months. The postoperative respiratory complication rate was 11% (10 patients), and included pneumonia (9) and acute respiratory distress syndrome (4). Multivariate analysis revealed that preoperative chemotherapy ( P = 0.012), preoperative radiotherapy ( P = 0.003), and Eastern Cooperative Oncology Group (ECOG) performance score 3 or 4 ( P = 0.013) were independent risk factors of OS after VATS talc pleurodesis. Conclusions We identified previous chemotherapy or radiotherapy and poor performance status (ECOG 3 or 4) as significant predictors of OS after VATS talc pleurodesis. These prognostic factors can help surgeons select candidates for VATS pleurodesis for malignant pleural effusion.
机译:背景恶性胸腔积液患者的预期寿命有限。胸膜和肿瘤治疗选择的增加以及更准确的预后评估可能有助于个体化治疗策略。这项研究的目的是确定整体胸腔镜手术治疗恶性胸腔积液的视频辅助胸腔手术(VATS)后的总生存期(OS)的预后指标。方法我们在三星医学中心检查了2006年至2008年连续接受VATS滑石粉胸膜固定术的所有恶性胸腔积液患者的病历。单因素和多因素分析用于确定VATS滑石胸膜固定术后OS的预测因素。结果在研究期间,有91例患者接受了VATS滑石粉胸膜固定术治疗恶性胸腔积液。术后早期(30天之内)和晚期(90天之内)的死亡率分别为9.9%(9例患者)和25.3%(23)。 VATS滑石胸膜固定术后的中位生存时间为10.5个月。术后呼吸系统并发症发生率为11%(10例),包括肺炎(9)和急性呼吸窘迫综合征(4)。多元分析表明,术前化疗(P = 0.012),术前放疗(P = 0.003)和东部合作肿瘤小组(ECOG)的性能评分为3或4(P = 0.013)是VATS滑石胸膜固定术后OS的独立危险因素。结论我们确定以前的化学疗法或放疗和不良的表现状态(ECOG 3或4)是VATS滑石胸膜固定术后OS的重要预测指标。这些预后因素可以帮助外科医生为恶性胸腔积液选择VATS胸膜固定术的候选人。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号